MedTrace Logo

The Effects of Bindarit in Diabetic Nephropathy

NCT01109212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-03-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether bindarit is effective to reduce albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a background therapy.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Bindarit

dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks

DRUG

Placebo

dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    collaborator OTHER

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Principal Investigators

  • Giuseppe Remuzzi, PhD · Mario Negri Institute for Pharmacological Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • Italy
  • Slovenia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109212 on ClinicalTrials.gov